# XTL Biopharmaceuticals Ltd. (XTLB)

Source: https://www.quantisnow.com/company/XTLB
Generated: 2026-11-12T00:25:12.129Z

- Ticker: XTLB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001023549
- Website: xtlbio.com

## About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

## Latest XTLB news and filings

- 2026-10-14 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6746540)
- 2026-08-05 20:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6665667)
- 2026-07-21 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6643791)
- 2026-06-30 21:24 UTC [SEC Form 20-F filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-xtl-biopharmaceuticals-ltd-6621322)
- 2026-06-30 21:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6621273)
- 2026-06-30 21:15 UTC [Mergers & Acquisitions] [XTL Completed the Acquisition of Psyga Bio Ltd.](https://www.quantisnow.com/insight/xtl-completed-the-acquisition-of-psyga-bio-ltd-6621260)
- 2026-06-29 20:39 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6619225)
- 2026-05-22 20:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6569751)
- 2026-05-22 20:10 UTC [XTL Announces Receipt of Staff Delist Determination from Nasdaq](https://www.quantisnow.com/insight/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-6569693)
- 2026-05-15 21:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6558357)
- 2026-05-07 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6537713)
- 2026-04-30 20:34 UTC [SEC Form NT 20-F filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-nt-20-f-filed-by-xtl-biopharmaceuticals-ltd-6525020)
- 2026-04-29 13:07 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6520477)
- 2026-04-29 12:58 UTC [XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies](https://www.quantisnow.com/insight/xtl-biopharmaceuticals-to-acquire-psyga-bio-establishing-a-leading-psychedelic-6520409)
- 2026-03-23 20:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Segal Niv](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-segal-niv-6464911)
- 2026-03-23 20:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hillel Fain Osnat](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hillel-fain-osnat-6464905)
- 2026-03-20 20:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6463266)
- 2026-03-20 20:10 UTC [XTL Biopharmaceuticals Announces ADS Ratio Change](https://www.quantisnow.com/insight/xtl-biopharmaceuticals-announces-ads-ratio-change-6463249)
- 2026-03-10 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6439532)
- 2026-02-27 21:34 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6419457)
- 2026-02-27 21:30 UTC [Leadership Update] [XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing](https://www.quantisnow.com/insight/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-and-6419300)
- 2026-02-24 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6409815)
- 2026-02-23 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6407062)
- 2026-02-17 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6395877)
- 2026-01-29 21:05 UTC [XTL Update on Recent Developments](https://www.quantisnow.com/insight/xtl-update-on-recent-developments-6365864)
- 2026-01-28 13:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6363491)
- 2026-01-23 21:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6359227)
- 2026-01-23 21:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6359226)
- 2026-01-23 21:10 UTC [XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency](https://www.quantisnow.com/insight/xtl-announces-receipt-of-nasdaq-notification-regarding-minimum-stockholders-equity-6359164)
- 2026-01-13 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6348039)
- 2026-01-13 12:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6347334)
- 2025-12-30 19:38 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6329712)
- 2025-12-29 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6328465)
- 2025-12-24 21:00 UTC [XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency](https://www.quantisnow.com/insight/xtl-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-6327546)
- 2025-12-12 22:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6314716)
- 2025-12-05 21:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6305232)
- 2025-10-23 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6243226)
- 2025-07-28 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6134330)
- 2025-07-21 15:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-xtl-biopharmaceuticals-ltd-6126534)
- 2025-06-18 21:00 UTC [SEC Form 6-K] [Amendment: SEC Form 6-K/A filed by XTL Biopharmaceuticals Ltd.](https://www.quantisnow.com/insight/amendment-sec-form-6-ka-filed-by-xtl-biopharmaceuticals-ltd-6092201)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/XTLB
- Earnings history: https://www.quantisnow.com/earnings/XTLB
- Dividend history: https://www.quantisnow.com/dividends/XTLB
- Insider transactions: https://www.quantisnow.com/insiders/XTLB
- Options chain: https://www.quantisnow.com/options/XTLB
- SEC 8-K filings only: https://www.quantisnow.com/company/XTLB/8-k
- RSS and alerts for XTLB: https://www.quantisnow.com/docs/rss-feeds.md